Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Analysts update Alizyme

This article was originally published in Scrip

Executive Summary

Piper Jaffrayanalysts have updated their forecast for Alizymeafter the company's second-half loss far exceeded expectations. Alizyme's net loss was £8.9 million, significantly higher than the £3.6 million predicted by the analysts (ScripOnline, September 1st, 2008). They reiterated their neutral recommendation as Alizyme ended the period with £7.7 million in cash, only slightly lower than their prediction of £8.4 million. However, the analysts reduced their price target from 10.1p to 8.1p and their forecast for Alizyme's year-end cash from £6.4 million to £2.6 million. Barring any further cost surprises, this should be enough to last the company until the end of next year, says Piper Jaffray.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC005059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel